# Dansk Erhvervsinvestering

> Dansk Erhvervsinvestering is a VC fund backing Medical, Health Care and Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 3
- Last investment: Jan 2007
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.dan-erhv.dk

Dansk Erhvervsinvestering is a company that assists individuals with investing.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 33% |
| Health Care | 1 | 33% |
| Biotechnology | 1 | 33% |
| Manufacturing | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| PremiTech | PremiTech A/S develops systems management software. It offers Performance Guard, a solution that enables IT departments to get real-time measurement of end-user application and infrastructure IT performance in software as a service model. The company also provides Performance Guard CIO Dashboard Module, which provides a view into the ITinfrastructures performance based on grouping by location and application; and Performance Guard Health Check Module that delivers reports on infrastructure components, including applications, mid-tier servers, network and PC Infrastructure for automated, out-of-the-box fast performance documentation, and issue resolution. In addition, it offers monitoring and documentation, and performance monitoring solutions. The company has strategic partnerships with HP, Computer Associates, BMC, VMWare, IBM, and Microsoft. PremiTech A/S was founded in 1999 and is headquartered in Hedehusene, Denmark. As of 2008, PremiTech A/S operates as a subsidiary of CapaSystems A/S. | $4M | Series D | Jan 29, 2007 |  |
| Genmab | Genmab is an international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's discovery, development, and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Its primary goal is to improve the lives ofpatients who are in urgent need of new treatment options. | $40.5M |  | Jun 13, 2000 |  |
| Genmab | Genmab is an international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's discovery, development, and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Its primary goal is to improve the lives ofpatients who are in urgent need of new treatment options. | $2M |  | May 17, 1999 |  |

3 of 3 investments shown.

## Co-investors
- [BankInvest Biomedical Venture](https://shizune.co/investors/profile/bankinvest-biomedical-venture) — VC Fund, 2 deals together
- [Apax Partners France](https://shizune.co/investors/profile/apax-partners-france) — VC Fund, 1 deal together
- [Index Ventures](https://shizune.co/investors/profile/index-ventures) — VC Fund, 1 deal together
- [LODH Immunology Fund](https://shizune.co/investors/profile/lodh-immunology-fund) — VC Fund, 1 deal together
- [Northcap](https://shizune.co/investors/profile/northcap) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden) — VC Fund
- [PSV](https://shizune.co/investors/profile/preseed-innovation) — VC Fund
- [Seed Capital](https://shizune.co/investors/profile/seed-capital) — VC Fund

## Featured in investor lists
- [Medical VC Funds in Denmark](https://shizune.co/investors/medical-vc-funds-denmark)
- [Manufacturing VC Funds in Denmark](https://shizune.co/investors/manufacturing-vc-funds-denmark)
- [Biotechnology VC Funds in Denmark](https://shizune.co/investors/biotechnology-vc-funds-denmark)
- [Health Care Investors in Denmark](https://shizune.co/investors/health-care-investors-denmark)
- [Biotech VC Funds in Denmark](https://shizune.co/investors/biotech-vc-funds-denmark)
- [Climate Investors in Denmark](https://shizune.co/investors/climate-investors-denmark)

## FAQ

### What does Dansk Erhvervsinvestering invest in?

Dansk Erhvervsinvestering invests primarily in Medical, Health Care and Biotechnology startups, most often at Funding Round stage. Most of the 3 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Dansk Erhvervsinvestering last invest?

The most recent investment recorded for Dansk Erhvervsinvestering closed in Jan 2007. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co